Elan reaffirms commitment to Tysabri

Pharmaceutical giant Elan is to press ahead with the development of its landmark MS drug Tysabri, it was announced today.

“In response to Biogen Idec Inc’s announcement on December 12, 2007 that it has completed its strategic review and will continue its present course as an independent company, Elan Corporation plc today reaffirmed its commitment to Tysabri and the patients who are and will benefit from this treatment,” the company said a statement.

“Specifically, Elan intends to continue to work effectively with Biogen Idec on securing FDA approval of the pending CD indication and realizing the full potential of Tysabri in the MS marketplace.

“Although Elan was not privy to the strategic evaluation process conducted by Biogen Idec since its October 12, 2007 announcement, Elan previously indicated its receptivity to the possible restructuring of its existing collaboration agreement in connection with a third party’s acquisition of Biogen Idec.”